248 related articles for article (PubMed ID: 33837922)
1. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
Uzoigwe C; Liang Y; Whitmire S; Paprocki Y
Diabetes Ther; 2021 May; 12(5):1475-1489. PubMed ID: 33837922
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
5. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
[TBL] [Abstract][Full Text] [Related]
6. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
8. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
Mody R; Yu M; Nepal B; Konig M; Grabner M
Diabetes Obes Metab; 2021 Jan; 23(1):106-115. PubMed ID: 32945083
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I
Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484
[TBL] [Abstract][Full Text] [Related]
10. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
11. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.
Heimbürger SM; Brønden A; Johansen NJ; Dejgaard TF; Vilsbøll T; Knop FK
Expert Opin Pharmacother; 2019 Apr; 20(5):501-510. PubMed ID: 30730773
[TBL] [Abstract][Full Text] [Related]
14. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
16. A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.
Webb N; Orme M; Witkowski M; Nakanishi R; Langer J
Diabetes Ther; 2018 Jun; 9(3):973-986. PubMed ID: 29574633
[TBL] [Abstract][Full Text] [Related]
17. Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.
Nuhoho S; Gupta J; Hansen BB; Fletcher-Louis M; Dang-Tan T; Paine A
Diabetes Ther; 2019 Dec; 10(6):2183-2199. PubMed ID: 31599391
[TBL] [Abstract][Full Text] [Related]
18. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
[TBL] [Abstract][Full Text] [Related]
19. A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.
Kayaniyil S; Lozano-Ortega G; Bennett HA; Johnsson K; Shaunik A; Grandy S; Kartman B
Diabetes Ther; 2016 Mar; 7(1):27-43. PubMed ID: 26886440
[TBL] [Abstract][Full Text] [Related]
20. Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.
Mody R; Manjelievskaia J; Marchlewicz EH; Malik RE; Zimmerman NM; Irwin DE; Yu M
Clin Ther; 2022 Apr; 44(4):537-554. PubMed ID: 35264311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]